Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia

Trial Profile

Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Status changed from recruiting to suspended.
    • 30 Jun 2017 Planned End Date changed from 1 Apr 2018 to 15 Apr 2018.
    • 30 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 15 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top